This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M35.1 (mixed connective tissue disease) | Special Copayment Reduction: V139 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first presentation in adulthood very high — mixed connective tissue disease is first diagnosed mainly in young adult women aged 15–35, and with its wide range of age at onset it presents from the late teens to the 50s. Pediatric onset occurs but is rare, and most patients first notice symptoms in adulthood as Raynaud phenomenon, hand swelling or arthritis. |
| 1. History | First described as an independent clinical entity by Sharp et al. in 1972 → discovery of anti-U1-RNP antibodies → classification criteria published by Alarcon-Segovia in 1987 and Kasukawa et al. in 1991 → ongoing debate over whether it is an independent disease → currently assigned a separate ICD-10 code, M35.1. |
| 2. Causes | Anti-U1-RNP autoantibodies are the key immune marker. Genetic predisposition (HLA-DR4, HLA-DRB1*04:01). Environmental triggers (viral infection). Autoimmune response to the U1-snRNP protein complex. Combined mechanisms of vascular endothelial injury, vascular proliferation and fibrosis. |
| 3. Genetics | Association with anti-U1-RNP antibodies is strongest for HLA-DR4 (DRB1*04:01). HLA-DRB1*01:01 and DRB1*01:02 also associated. PTPN22 and STAT4 variants related. Polygenic complex inheritance. Familial clustering rare but present. |
| 4. General epidemiology | Prevalence about 3–6/100,000. Female:male about 8–16:1. Peak onset at 15–35 years. About 2,000–4,000 registered with Korean rare disease registration (estimated). Pulmonary arterial hypertension is the main cause of death (occurring in about 10–25%). |
| 5. Pathophysiology | Cell surface exposure of U1-snRNP during apoptosis → production of anti-U1-RNP autoantibodies → B cell and T cell activation → vascular endothelial injury and vascular smooth muscle proliferation → development of PAH. Excess TGF-β → some fibrosis. |
| 6. Symptoms | Raynaud phenomenon (common early), swelling of the hands and fingers (sausage fingers), arthritis (mainly small joints of the hands), muscle weakness (myositis), esophageal dysmotility, skin sclerosis (sclerodactyly), pulmonary arterial hypertension (exertional dyspnea), trigeminal neuralgia. |
| 7. Signs | Sausage-like swelling of the hands and fingers (puffy fingers), sclerodactyly, arthritis (often nondeforming), proximal muscle weakness (myositis), nailfold capillaroscopy abnormalities, high-titer positive anti-U1-RNP antibodies, speckled-pattern positive ANA. |
| 8. Screening | In patients with a combination of Raynaud phenomenon + hand swelling + arthritis, test for ANA (speckled pattern) and anti-U1-RNP antibodies. After confirmation, PAH screening (annual echocardiography) and PFT (ILD screening). Regular measurement of muscle enzymes (CK). |
| 9. Diagnosis | Of the Sharp, Alarcon-Segovia and Kasukawa criteria, the Alarcon-Segovia criteria are the most widely used clinically. Core: high-titer anti-U1-RNP antibodies + 3 or more of hand swelling, sclerodactyly, Raynaud phenomenon, polyarthritis and myositis. Differentiation from SLE, systemic sclerosis and polymyositis overlap is essential. |
| 10. Treatment | Mild: hydroxychloroquine, NSAIDs. Moderate: steroids (0.5 mg/kg/day). Myositis: steroids + MTX/AZA. PAH: combination of ERA + PDE-5 inhibitor. ILD: MMF, nintedanib. Raynaud: CCB, PDE-5 inhibitor. Rituximab (severe extraglandular involvement). |
| 11. Prognosis | Better than lupus, worse than systemic sclerosis. 10-year survival about 80–85%. Main cause of death: PAH. In the long term, some "differentiate" into lupus, systemic sclerosis or polymyositis. Good steroid response makes the prognosis optimistic early on, but it worsens sharply when PAH develops. |
| 12. Prevention | Primary: no established prevention; smoking cessation, avoidance of cold. Secondary: early anti-U1-RNP screening with a combination of Raynaud phenomenon + hand swelling. Tertiary: annual PAH screening (echocardiography), PFT, muscle enzymes, follow-up of skin changes, maintenance of the minimum effective steroid dose. |
| 13. References | Sharp GC, et al. Mixed connective tissue disease. Am J Med. 1972 … and 9 other papers |
The history of mixed connective tissue disease (MCTD) begins in 1972, when the American rheumatologist Gordon Sharp and colleagues first described it as an independent clinical entity. Sharp et al. analyzed 25 patients who had overlapping features of systemic lupus erythematosus (SLE), systemic sclerosis and polymyositis and who commonly had high-titer anti-U1-RNP (U1 small nuclear ribonucleoprotein) antibodies, and argued that they constituted an independent disease category different from any existing disease. Sharp et al. reported that this new disease commonly showed high-titer positive anti-U1-RNP antibodies, hand swelling, Raynaud phenomenon, myositis, arthritis and esophageal dysmotility, and that it had a better steroid response and a more favorable prognosis than SLE or systemic sclerosis. This landmark paper was published in the American Journal of Medicine in 1972, after which the name MCTD came into international use.
During the 1970s–80s, research on the clinical features of MCTD, the immunologic characteristics of anti-U1-RNP antibodies and the long-term course was active. Anti-U1-RNP antibodies were found to target proteins that make up the U1-snRNP complex (U1-70K, U1-A, U1-C and Sm proteins), and high-titer positivity for this antibody was established as the key immunologic feature of MCTD. However, because anti-U1-RNP antibodies are also positive in about 25–30% of SLE and MCTD sometimes "evolves" over the long term into features of lupus or systemic sclerosis, debate continued over whether MCTD is a truly independent disease or part of an autoimmune spectrum.
In terms of classification criteria, in 1987 Alarcon-Segovia and Villareal published the criteria most widely used in clinical practice, and in 1991 Kasukawa et al. of Japan proposed separate criteria. Sharp's original criteria have also been revised several times and remain in use. All of these criteria require anti-U1-RNP antibody positivity as an essential condition and make the diagnosis from a combination of clinical findings (hand swelling, Raynaud phenomenon, sclerodactyly and hand swelling, polyarthritis, myositis, esophageal dysmotility, lung involvement, etc.). To date there is no internationally agreed single set of classification criteria, and development of updated classification criteria is under way in a research initiative led by the European League Against Rheumatism (EULAR) in 2019. The code M35.1 is assigned in ICD-10, and in Korea it is designated for rare disease Special Copayment Reduction (V139).
Pulmonary arterial hypertension (PAH) emerged as a main cause of death in patients with MCTD after the 1980s–90s, and as studies accumulated showing that the incidence of PAH in MCTD is higher than in other connective tissue diseases such as SLE, the importance of early detection and treatment of PAH was emphasized. In Korea, management guidelines for patients with MCTD are being developed mainly by the Korean College of Rheumatology and the Korean Association of Internal Medicine, and research on the clinical and genetic characteristics of Korean patients with MCTD is also under way.
The cause of mixed connective tissue disease (MCTD) is understood as a complex interaction of an autoimmune response centered on anti-U1-RNP antibodies, genetic predisposition and environmental triggers.
Anti-U1-RNP autoantibodies and the U1-snRNP complex: the most characteristic immunologic marker of MCTD is the anti-U1-RNP (anti-U1 small nuclear ribonucleoprotein) antibody, which is positive at high titer in almost 100% of patients with MCTD. U1-snRNP is part of the small nuclear ribonucleoprotein (spliceosome) complex involved in pre-mRNA splicing and consists of the U1-70K, U1-A, U1-C, Sm-B/B' and Sm-D1/D2/D3 proteins. During apoptosis, the U1-snRNP complex is exposed on apoptotic bodies at the cell surface and presented to the immune system, activating autoreactive B cells and T cells to produce anti-U1-RNP antibodies. Some studies report that anti-U1-RNP antibodies themselves contribute to direct tissue damage through vascular endothelial cell injury, stimulation of type I interferon secretion and complement activation.
Mechanism of vascular lesions: the characteristic vascular lesion of MCTD is intimal proliferative vasculopathy. As endothelial cell proliferation, smooth muscle cell migration and proliferation, and intimal thickening progress in small vessels, pulmonary vascular resistance increases and PAH develops. Unlike PAH in systemic sclerosis, PAH in MCTD has a more prominent vascular inflammatory component, which is interpreted as the reason it may respond to immunosuppressive therapy (steroids + immunosuppressants) early in PAH. Proposed initial triggering mechanisms of vascular endothelial injury include direct injury by anti-U1-RNP antibodies, type I interferon-mediated endothelial activation and T cell-mediated vascular inflammation.
Environmental triggers: there is a hypothesis that viral infections, particularly Epstein-Barr virus (EBV) and retroviruses, can trigger MCTD through a mechanism of molecular mimicry with U1-snRNP. Ultraviolet light, estrogen, stress and others are also proposed as potential triggers. Occupational silica exposure has been reported as a risk factor for MCTD-like syndromes, as for systemic sclerosis.
Mechanism of fibrosis: fibrosis in MCTD is not as prominent as in systemic sclerosis, but in some patients esophageal smooth muscle fibrosis, pulmonary fibrosis (ILD) and sclerodactyly progress. Excessive secretion of TGF-β1 and PDGF is known to contribute to this limited fibrosis.
Mixed connective tissue disease (MCTD) is a polygenic, complex-inheritance autoimmune disease, and HLA gene associations are the most clearly established genetic susceptibility factors.
HLA associations: the association between HLA-DR4 (DRB1*04:01) and anti-U1-RNP antibody-positive MCTD is reported most strongly and consistently. This association is particularly prominent in patients of European descent and is explained by the structural property of HLA-DR4 that efficiently presents U1-snRNP protein antigens on MHC II molecules. HLA-DRB1*01:01 and DRB1*01:02 have also been identified as risk alleles in some studies. The HLA association pattern in East Asian patients, including Koreans, may differ from that in Western patients, and some studies have reported associations with HLA-DQ alleles in addition to HLA-DRB1*04. Protective HLA alleles have not yet been clearly established.
Non-HLA genetic associations: MCTD shares many non-HLA susceptibility genes with other autoimmune diseases. PTPN22 (protein tyrosine phosphatase non-receptor type 22): regulates adaptive immune responses and the activation thresholds of T cells and B cells. The R620W gain-of-function variant is associated with several autoimmune diseases (RA, SLE, MCTD). STAT4: IFN-γ and IL-12 signaling pathways, amplification of Th1 responses; an association has also been reported in anti-U1-RNP-positive patients. IRF5: amplification of the type I interferon signaling pathway. A susceptibility gene shared by MCTD and SLE. In addition, genes related to immune synapse formation, cell signaling and regulation of apoptosis are being studied as candidate susceptibility factors.
Association of genetics with phenotype: some studies suggest an association between the long-term clinical course of MCTD (differentiation into lupus vs. differentiation into systemic sclerosis vs. remaining stable MCTD) and HLA genotype. There are reports that systemic sclerosis-like features (severity of Raynaud phenomenon, sclerodactyly) tend to be more prominent in HLA-DR4-positive patients, but these are results of small studies and are not yet established. Familial clustering is rarer in MCTD than in other autoimmune diseases, but the risk of onset is slightly higher in those with a family history of autoimmune disease.
Anti-U1-RNP and epigenetics: epigenetic mechanisms involved in the production and maintenance of anti-U1-RNP antibodies (particularly abnormal DNA methylation and altered miRNA expression in T cells and B cells) are being studied. Epigenetic abnormalities shared with SLE (particularly hypomethylation of IFN signaling-related genes) are also observed in MCTD. These epigenetic changes partly explain the phenotypic overlap between MCTD and SLE.
Mixed connective tissue disease (MCTD) is a rare autoimmune connective tissue disease, with a worldwide prevalence reported at about 3–6 per 100,000 population. However, because of the diversity of diagnostic criteria and diagnostic delay, the actual prevalence is presumed to be higher.
Sex and age distribution: MCTD occurs overwhelmingly in women, with a female:male ratio reported at about 8–16:1. Age at onset is highest in young adult women aged 15–35; onset also occurs in middle-aged women, but onset in old age is rare. Juvenile MCTD is also reported and shows clinical features similar to those in adults, though some studies indicate that PAH and renal involvement are more common. The high incidence in young women is interpreted as related to the immunomodulatory role of estrogen.
Regional differences in prevalence: relatively high prevalence is observed in Northern Europe; in Norway, for example, the prevalence of MCTD is reported at about 3.8 per 100,000 population. In Japan, MCTD is an independent rare intractable disease covered by the national registration system, with a prevalence reported at about 2–3/100,000. In Korea, based on the number of patients registered for rare disease Special Copayment Reduction (V139) and health insurance claims data, about 2,000–4,000 people are estimated to receive care for MCTD. Korean patients also show female predominance, peak onset in young adults and high-titer anti-U1-RNP antibody positivity, similar to Western patients.
Incidence of PAH: the incidence of pulmonary arterial hypertension (PAH) in MCTD is reported at about 10–25%, similar to or slightly higher than in systemic sclerosis (about 10–20%). Because PAH sometimes develops years to decades after diagnosis, continuous surveillance is needed. PAH is the main cause of death in patients with MCTD, and when steroid-unresponsive progressive PAH develops, the prognosis worsens greatly. ILD accompanies about 15–30%, mainly with an NSIP pattern.
Disease evolution: on long-term follow-up, about 25–40% of patients with MCTD "differentiate" toward features of systemic sclerosis or SLE. In patients who differentiate into systemic sclerosis, skin sclerosis, ILD and PAH become prominent, and those who differentiate into SLE develop glomerulonephritis, cytopenias and anti-dsDNA antibody positivity. The remaining approximately 60–75% retain the features of MCTD in the long term or stabilize clinically.
The pathophysiology of mixed connective tissue disease (MCTD) centers on an autoimmune response to the U1-snRNP complex and is understood as a cascade leading to multiple pathologies, including vascular injury, innate immune activation and fibrosis.
U1-snRNP antigen exposure and autoantibody production: as apoptosis proceeds, the U1-snRNP complex is exposed on apoptotic bodies at the cell surface. The exposed U1-snRNP proteins (U1-70K, U1-A, U1-C) are phagocytosed by antigen-presenting cells (dendritic cells, macrophages) and presented on MHC II molecules. In individuals with susceptible HLA alleles such as HLA-DR4, CD4+ T helper cells are effectively activated and stimulate anti-U1-RNP-specific B cells, inducing production of high-titer anti-U1-RNP antibodies. These antibodies form circulating immune complexes with the U1-snRNP complex in the blood, which deposit in vessel walls, renal glomeruli, joints and elsewhere and trigger complement activation and Fc receptor-mediated inflammatory responses.
Type I interferon and innate immunity: U1-snRNP complexes bound to anti-U1-RNP antibodies stimulate TLR7 (single-stranded RNA recognition) on plasmacytoid dendritic cells (pDC), causing secretion of large amounts of type I interferon (IFN-α). An "interferon signature" is strongly observed in the blood of patients with MCTD, similar to SLE. Type I interferon amplifies adaptive immune activation and induces BAFF-mediated promotion of B cell survival and antibody production, as well as endothelial cell activation.
Vascular lesions and the development of PAH: the most important vascular lesions in MCTD are intimal hyperplasia and medial hypertrophy of small pulmonary arteries. Anti-U1-RNP antibodies bind to the surface of pulmonary vascular endothelial cells, activating complement and causing endothelial injury. Injured endothelial cells promote vascular smooth muscle cell migration and proliferation and vascular fibrosis through excessive endothelin-1 secretion, reduced nitric oxide synthesis and increased PDGF secretion. Because PAH in MCTD has an inflammatory vasculopathy component, it sometimes improves early with immunosuppressive therapy (steroids + immunosuppressants), a therapeutic feature that distinguishes it from idiopathic PAH or PAH in systemic sclerosis.
Mechanism of myositis: CD8+ cytotoxic T cells infiltrate muscle fibers that aberrantly express MHC I and cause muscle fiber necrosis via the perforin/granzyme pathway. U1-RNP antigens are also expressed in muscle cells, so antibody-mediated injury may contribute. Myositis in MCTD tends to respond better to treatment and to have a more favorable prognosis than polymyositis/dermatomyositis.
The clinical symptoms of mixed connective tissue disease (MCTD) present as a "mixture" of features of systemic lupus erythematosus, systemic sclerosis and polymyositis, and the features may change over time in the same patient.
Raynaud phenomenon: occurs in about 85–95% of all patients with MCTD and is in many cases the earliest symptom of MCTD. It is characterized by a triphasic color change of the fingers (sometimes toes) — pallor → cyanosis → redness — on exposure to cold temperatures or emotional stress. Unlike primary Raynaud phenomenon, Raynaud phenomenon in MCTD is accompanied by nailfold capillaroscopy abnormalities and in some cases progresses to ischemic ulcers of the fingertips.
Puffy hands/fingers: non-pitting swelling of the hands and fingers, also called sausage-like swelling, is a very characteristic finding of MCTD and is prominent early in diagnosis. Symptoms of stiff, swollen hands on waking in the morning appear together with joint stiffness. This swelling is a combination of dermal edema and early skin sclerosis, and early differentiation from systemic sclerosis is needed.
Arthritis: polyarthritis occurs in about 60–80% of patients. It mainly affects the small joints of the hands (PIP, MCP), wrists, knees and ankles and may be symmetric or asymmetric. It is initially nonerosive and nondeforming, but over the long term some cases progress to joint damage resembling rheumatoid arthritis. Joint pain and stiffness are the most common symptoms.
Myositis: proximal muscle weakness and myalgia occur in about 30–60%, and histologically show inflammatory findings similar to polymyositis or dermatomyositis. Elevated muscle enzymes such as CK and LDH are present. Myositis in MCTD generally responds well to steroids. The characteristic skin findings of dermatomyositis (heliotrope rash, Gottron papules) are rare in MCTD but may occur.
Esophageal dysmotility and gastrointestinal symptoms: lower esophageal dysmotility occurs in about 60–70% and, as in systemic sclerosis, presents as dysphagia for solids, gastroesophageal reflux and postprandial chest discomfort. Esophageal manometry shows reduced lower esophageal sphincter pressure and loss of peristalsis. Bacterial overgrowth and malabsorption due to small bowel dysmotility may also occur.
Pulmonary arterial hypertension and pulmonary symptoms: PAH occurs in about 10–25% of patients with MCTD and presents with progressive exertional dyspnea, fatigue, chest pain and syncope. ILD accompanies about 15–30% and causes dry cough and exertional dyspnea. Pleuritis also occurs in about 20–30%.
The physical signs of mixed connective tissue disease (MCTD) consist of diverse findings combining the features of several connective tissue diseases.
Vascular and skin signs: non-pitting sausage-like swelling of the hands and fingers feels soft and elastic on palpation. Sclerodactyly (skin sclerosis of the fingers) may appear from the early stage and, unlike in systemic sclerosis, does not readily spread to the trunk. Nailfold capillaroscopy shows a systemic sclerosis-like pattern (giant capillaries, capillary loss). Telangiectasia appears in about 30–40%. As for skin rashes, an SLE-like butterfly-shaped malar rash, photosensitive rash and discoid erythema appear in some.
Joint and muscle signs: polyarticular swelling, tenderness and stiffness occur. Over the long term, deformity of the hand joints may appear (MCTD is generally nonerosive, but some may develop Jaccoud arthropathy-like nonerosive deformity). Proximal muscle weakness (upper limbs: deltoid; lower limbs: quadriceps) and proximal muscle tenderness appear when myositis is active. A tendon friction rub is palpated in some.
Pulmonary and cardiac signs: with ILD, basal Velcro crackles (fine crackles) are heard on auscultation. As PAH progresses, signs of right heart failure appear, such as an accentuated P2, a palpable right ventricular heave at the left sternal border, jugular venous distension and lower limb edema. With pleural effusion, a pleural friction rub, dullness to percussion and reduced breath sounds are observed.
Serologic signs: high-titer anti-U1-RNP antibodies (≥1:1,600, or a high titer on quantitative testing) are the key serologic marker of MCTD. ANA is typically positive at high titer (≥1:160) with a speckled pattern. Anti-Scl-70, anti-centromere, anti-dsDNA and anti-Sm are negative or low titer. However, when anti-Sm is positive, the possibility of overlap with SLE is considered. Hypergammaglobulinemia, RF positivity (about 50–70%), and mild anemia and thrombocytopenia may occur.
Screening for mixed connective tissue disease (MCTD) begins with autoantibody screening in patients with the characteristic combination of Raynaud phenomenon and hand swelling. After confirmation, regular screening for major complications such as PAH is key.
Initial MCTD screening: in adult women with a combination of Raynaud phenomenon + swelling of the hands and fingers (puffy fingers/hands) + arthritis or muscle weakness, MCTD is suspected immediately and autoantibody screening is performed. ANA (confirmation of speckled pattern) and anti-U1-RNP antibodies are measured together. If anti-U1-RNP antibodies are positive at high titer (≥1:1,600 or positive on quantitative testing), MCTD is very likely, so immediate specialist referral and further evaluation are carried out. A systemic sclerosis-like vascular pattern is checked with nailfold capillaroscopy.
PAH screening (confirmed patients): because the incidence of PAH is high in MCTD, annual echocardiography (estimated sPAP measurement, assessment of right heart function) and pulmonary function tests (FVC, DLCO) are performed after confirmation. An isolated reduction in DLCO or an increased FVC/DLCO ratio is an early indicator of PAH. When echocardiography shows sPAP ≥ 40 mmHg or DETECT-like algorithm criteria are met, the diagnosis is confirmed by right heart catheterization. Early detection is particularly important in MCTD because PAH may stabilize with immunosuppressive therapy after early detection.
ILD screening: chest HRCT is performed when there are respiratory symptoms (exertional dyspnea, dry cough) or PFT abnormalities (reduced FVC, DLCO). Even without symptoms, baseline PFT and chest HRCT are performed early in diagnosis, and follow-up PFT every 6–12 months thereafter is recommended.
Myopathy screening: when proximal muscle weakness or myalgia is present, CK, LDH and aldolase are measured immediately, and if abnormal, EMG and muscle MRI are performed. Even without symptoms, asymptomatic myositis is detected early by regular CK measurement (every 6–12 months).
The diagnosis of mixed connective tissue disease (MCTD) uses classification criteria combining clinical findings with high-titer anti-U1-RNP antibody positivity. There is no internationally agreed single set of criteria, but the Alarcon-Segovia criteria are the most widely used in clinical practice.
Alarcon-Segovia criteria (1987): serologic criterion (required): high-titer anti-U1-RNP antibody positivity (≥1:1,600 on ENA testing or equivalent quantitative positivity). Clinical criteria (3 or more of the following 5): ① edema of the hands ② synovitis (polyarthritis) ③ myositis with muscle biopsy findings or CK elevation ④ Raynaud phenomenon ⑤ sclerodactyly or proximal skin sclerosis of the hands. The sensitivity of the Alarcon-Segovia criteria is reported at about 73% and the specificity at about 94%.
Kasukawa criteria (1987): common symptoms (Raynaud phenomenon or hand swelling) + anti-U1-RNP antibody positivity + one or more symptoms from each of the following three diseases: SLE-like (butterfly rash, photosensitivity, oral ulcers, alopecia, thrombocytopenia, leukopenia, anti-dsDNA), systemic sclerosis-like (sclerodactyly, pulmonary fibrosis, esophageal dysmotility, PAH), polymyositis-like (muscle weakness, CK elevation, EMG abnormalities). They are used more often in Asian countries (Japan, Korea).
Differential diagnosis: the main conditions to differentiate are anti-Sm-positive SLE (even if anti-U1-RNP is positive, SLE takes precedence when anti-Sm coexists), anti-Scl-70- or anti-RNAP III-positive systemic sclerosis, anti-Jo-1-positive antisynthetase syndrome, antisynthetase syndrome and undifferentiated connective tissue disease (UCTD, undifferentiated CTD). UCTD refers to cases with autoimmune symptoms and autoantibody positivity that do not meet the criteria for a specific disease, and it may be a precursor or early stage of MCTD.
Initial evaluation after diagnosis: after confirmation, pulmonary function (FVC, DLCO), echocardiography (PAH baseline), chest HRCT (ILD baseline), renal function (creatinine, urinalysis), blood counts (CBC), muscle enzymes (CK, LDH) and hand X-rays (baseline joint involvement) are performed. This initial evaluation becomes the reference point for long-term follow-up.
The principle of treatment for mixed connective tissue disease (MCTD) is a stepwise approach according to disease activity, organs involved and severity. Early mild disease characteristically responds well to steroids, but once PAH progresses, treatment is difficult.
Mild MCTD: when arthralgia, myalgia and fatigue are the main symptoms, hydroxychloroquine (HCQ, 200–400 mg/day) is used first line. HCQ is effective for immunomodulation, reduction of cardiovascular risk and improvement of quality of life, and has a good long-term safety profile. NSAIDs are used adjunctively for arthritis and pleuritis, but caution is needed in patients with renal impairment. For Raynaud phenomenon, a calcium channel blocker such as amlodipine is used first line.
Moderate MCTD (systemic activity): for active arthritis, myositis, serositis and cytopenias, prednisone (0.5 mg/kg/day) is used as initial treatment. As steroid-sparing agents to allow steroid tapering, MTX (15–25 mg weekly) and AZA (1–2 mg/kg/day) are used first line. Myositis in MCTD responds relatively well to steroids, with normalization of muscle enzymes and recovery of muscle strength usually within 4–8 weeks.
Treatment of PAH: because MCTD-PAH has an inflammatory vasculopathy component that responds early to immunosuppressive therapy (steroids + immunosuppressants), high-dose steroids (prednisone 1 mg/kg/day) are combined with cyclophosphamide or MMF as soon as it is detected. At the same time, pulmonary vascular targeted therapy (ERA: ambrisentan, macitentan; PDE-5 inhibitors: sildenafil, tadalafil; prostacyclin analogues) is started immediately. If there is no improvement with immunosuppressive therapy, pulmonary vascular targeted therapy is actively intensified. MCTD-PAH may be more responsive to immunosuppressive therapy than idiopathic PAH, but the prognosis is poor once it progresses.
Treatment of ILD: for active ILD, MMF or AZA is used first line, and with progression, addition of cyclophosphamide or nintedanib is considered. Steroids are used adjunctively in early ILD with an inflammatory component. For esophageal dysmotility, long-term PPI administration and dietary modification are fundamental.
Severe or treatment-resistant MCTD: there is observational evidence that rituximab (RTX, anti-CD20) is effective in severe extraglandular involvement (vasculitis, treatment-resistant myositis, severe arthritis, cytopenias). RTX is reported to contribute to reduced anti-U1-RNP antibody titers and improved disease activity. Belimumab (an anti-BAFF monoclonal antibody) may also be considered in some patients with MCTD-SLE overlap features. Autologous hematopoietic stem cell transplantation (ASCT) is considered in extremely selected patients with severe refractory MCTD.
The prognosis of mixed connective tissue disease (MCTD) is better than that of systemic sclerosis, and it has traditionally been known to respond well to steroids, but when PAH develops the prognosis worsens dramatically and long-term mortality increases.
Survival and causes of death: the 10-year survival of MCTD is reported at about 80–85%, slightly lower than SLE (about 90–95%) and better than systemic sclerosis (dcSSc about 55–70%). The main cause of death is pulmonary arterial hypertension (PAH), accounting for about 30–40% of all MCTD-related deaths. Other reported causes of death include infection (particularly opportunistic infection during immunosuppressive therapy), cardiac involvement (myocarditis, pericarditis), renal involvement and cardiovascular and cerebrovascular disease. Some studies indicate that the risk of malignancy is similar to or slightly higher than in the general population.
Impact of PAH on prognosis: in patients with MCTD who develop PAH, mortality within 3–5 years is very high without treatment. After the introduction of targeted vascular therapy, 5-year survival improved to about 50–60%, similar to SSc-PAH. There are studies suggesting that the prognosis of MCTD-PAH may be slightly better than idiopathic PAH or PAH in systemic sclerosis when immunosuppressive therapy and vascular targeted therapy are combined, but the level of evidence is still low. Six-minute walk distance, NT-proBNP and right heart hemodynamic indices (mPAP, PVR) are used to monitor the prognosis of PAH.
Disease evolution and long-term course: about 25–40% of patients with MCTD "differentiate" over the long term in a direction in which features of SLE or systemic sclerosis become prominent. Depending on the direction of differentiation, they follow the prognostic characteristics of each disease. The remaining patients retain the features of MCTD or stabilize clinically, and in them adverse effects of long-term steroid use (osteoporosis, infection, diabetes, cataracts) become the main causes of morbidity. Appropriate steroid-sparing strategies and HCQ maintenance are important for improving long-term prognosis.
Quality of life and follow-up: arthritis, Raynaud phenomenon, fatigue, dry mouth and dry eyes (Sjögren overlap) and depression reduce quality of life. Multidisciplinary support is needed to maintain work capacity and social participation. At regular follow-up, a comprehensive assessment is performed, including ESSDAI-like activity assessment, PAH surveillance (echocardiography, 6MWT, NT-proBNP), ILD (PFT), muscle enzymes, blood counts and liver and renal function. Patients registered for Korean Special Copayment Reduction (V139) receive reduced medical costs.
There is no established method to prevent the onset of mixed connective tissue disease (MCTD), and prevention strategies focus on early detection and prevention of complications.
Primary prevention (reducing the risk of onset): there is currently no established method to directly prevent the onset of MCTD. Hygiene and vaccination to prevent viral infections (EBV, etc.) may help indirectly. Because smoking worsens vascular endothelial injury and Raynaud phenomenon, smoking cessation is recommended. Because ultraviolet light can worsen SLE-like skin reactions, photoprotection (sunscreen, UV-protective clothing) is recommended.
Secondary prevention (early detection): in young adult women with a combination of Raynaud phenomenon and hand swelling, or with unexplained arthritis, muscle weakness or fatigue, ANA and anti-U1-RNP antibody screening is performed immediately. After early diagnosis, HCQ-based treatment is started and baseline assessment of PAH and ILD is performed immediately. When high-titer anti-U1-RNP antibody positivity is confirmed in a patient being followed for undifferentiated connective tissue disease (UCTD), diagnosis of MCTD and intensified follow-up are needed.
Tertiary prevention (suppressing progression of complications): in confirmed patients, PAH is detected early with annual echocardiography, and immunosuppressive therapy and vascular targeted therapy are started immediately in early PAH. Avoidance of cold (warm gloves and clothing, maintaining indoor temperature) reduces the frequency and severity of Raynaud attacks. Maintaining the minimum effective steroid dose and long-term HCQ administration simultaneously suppress steroid adverse effects and disease relapse. Osteoporosis prevention (vitamin D and calcium supplementation, bisphosphonates) and management of cardiovascular risk factors (smoking cessation, control of blood pressure, glucose and lipids) are carried out. Vaccinations (influenza, pneumococcal, varicella-zoster) are kept up to date, and education on preventing opportunistic infections during immunosuppressive therapy is strengthened. Physical and occupational therapy maintain joint and hand function and build muscle strength.
Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-159. DOI: 10.1016/0002-9343(72)90064-2. PMID: 4621694.
Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp G (eds). Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Elsevier; 1987:33-40. ISBN: 9780444808325.
Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds). Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Elsevier; 1987:41-47.
Hajas A, Szodoray P, Nakken B, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol. 2013;40(7):1134-1142. DOI: 10.3899/jrheum.121272. PMID: 23637320.
Flam ST, Gunnarsson R, Garen T, et al. The Oslo MCTD cohort study; new patients are not clinically different from previously diagnosed patients. Rheumatology (Oxford). 2021;60(3):1174-1183. DOI: 10.1093/rheumatology/keaa465. PMID: 32886121.
Vegh J, Szodoray P, Kappelmayer J, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol. 2006;64(1):69-76. DOI: 10.1111/j.1365-3083.2006.01780.x. PMID: 16784487.
Reiseter S, Gunnarsson R, Mogens Aalokken T, et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease. Rheumatology (Oxford). 2018;57(2):255-262. DOI: 10.1093/rheumatology/kex304. PMID: 29029187.
Gunnarsson R, Aalokken TM, Molberg O, et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease. Rheumatology (Oxford). 2012;51(5):882-891. DOI: 10.1093/rheumatology/ker397. PMID: 22258390.
Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26(1):61-72. DOI: 10.1016/j.berh.2012.01.009. PMID: 22424194.
Kim HA, Yun JS, Lee SH, et al. Pulmonary arterial hypertension in Korean patients with mixed connective tissue disease: clinical features and outcome. Korean J Intern Med. 2020;35(1):111-119. DOI: 10.3904/kjim.2018.074. PMID: 30840778.